The ups and downs of Wnt signaling in prevalent neurological disorders

Oncogene

Volumn 25, Issue 57, 2006, Pages 7545-7553

  De Ferrari, G V ^a,b   Moon, R T ^b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Autism; Genetic variation; Schizophrenia; Wnt signaling

Indexed keywords

APOLIPOPROTEIN E; BETA CATENIN; FRIZZLED PROTEIN; WNT PROTEIN;

ALLELE; ALZHEIMER DISEASE; AUTISM; CELL COMMUNICATION; CORRELATION ANALYSIS; CYTOSKELETON; DEGENERATIVE DISEASE; DNA POLYMORPHISM; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; NERVE CELL; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; AUTISTIC DISORDER; GENE EXPRESSION REGULATION; HUMANS; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; VARIATION (GENETICS); WNT PROTEINS;

EID: 33845350346     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210064     Document Type: Review

References (161)

1. Abu-Khalil A, Fu L, Grove EA, Zecevic N, Geschwind DH. (2004). Wnt genes define distinct boundaries in the developing human brain: implications for human forebrain patterning. J Comp Neurol 474: 276-288.
2. Ahn YM, Seo MS, Kim SH, Kim Y, Yoon SC, Juhnn YS et al. (2005). Increased phosphorylation of Ser473-Akt, Ser9-GSK-3beta and Ser133-CREB in the rat frontal cortex after MK-801 intraperitoneal injection. Int J Neuropsychopharmacol 8: 607-613.
3. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. (2005a). Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 57: 533-542.
4. Alimohamad H, Sutton L, Mouyal J, Rajakumar N, Rushlow WJ. (2005b). The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J Neurochem 95: 513-525.
5. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. (2004). Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297: 186-196.
6. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. (2002). Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 4: 153-165.
7. Baader SL, Sanlioglu S, Berrebi AS, Parker-Thornburg J, Oberdick J. (1998). Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions. J Neurosci 18: 1763-1773.
8. Bailer U, Leisch F, Meszaros K, Lenzinger E, Willinger U, Strobl R et al. (2002). Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry 52: 40-52.
9. Barrett S, Beck JC, Bernier R, Bisson E, Braun TA, Casavant TL et al. (1999). An autosomal genomic screen for autism. Collaborative linkage study of autism. Am J Med Genet 88: 609-615.
10. Bartlett CW, Gharani N, Millonig JH, Brzustowicz LM. (2005). Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. Int J Dev Neurosci 23: 221-234.
11. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I et al. (2001). Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 302: 117-120.
12. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, Kamdar S et al. (2005). Support for the homeobox transcription factor gene ENGRAILED 2 as an autism spectrum disorder susceptibility locus. Am J Hum Genet 77: 851-868.
13. Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C et al. (2004a). A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 355: 37-40.
14. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E. (2004b). A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 368: 123-126.
15. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C et al. (2005). Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 376: 51-55.
16. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H et al. (2003). Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet 12: 23-32.
17. Blomqvist ME, Andreasen N, Bogdanovic N, Blennow K, Brookes AJ, Prince JA. (2004). Genetic variation in CTNNA3 encoding alpha-3 catenin and Alzheimer's disease. Neurosci Lett 358: 220-222.
18. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G et al. (1998). Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 20: 70-73.
19. Brown SD, Twells RC, Hey PJ, Cox RD, Levy ER, Soderman AR et al. (1998). Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem Biophys Res Commun 248: 879-888.
20. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X et al. (2005). Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 65: 2537-2541.
21. Busby V, Goossens S, Nowotny P, Hamilton G, Smemo S, Harold D et al. (2004). Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med 5: 133-146.
22. Buxbaum JD, Silverman JM, Smith CJ, Kilifarski M, Reichert J, Hollander E et al. (2001). Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. Am J Hum Genet 68: 1514-1520.
23. Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA et al. (2003). The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci 24: 233-238.
24. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A et al. (2004). Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 24: 6021-6027.
25. Chakravarti A. (2001). To a future of genetic medicine. Nature 409: 822-823.
26. Chen G, Huang LD, Jiang YM, Manji HK. (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330.
27. Chen J, Park CS, Tang SJ. (2006). Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol Chem 281: 11910-11916.
28. Chenn A, Walsh CA. (2002). Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297: 365-369.
29. Chenn A, Walsh CA. (2003). Increased neuronal production, enlarged forebrains and cytoarchitectural distortions in beta-catenin overexpressing transgenic mice. Cereb Cortex 13: 599-606.
30. Christianson AL, Chesler N, Kromberg JG. (1994). Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 36: 361-369.
31. Ciani L, Salinas PC. (2005). WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci 6: 351-362.
32. Collaborative Linkage Study of Autism. (2001). An autosomal genomic screen for autism. Am J Med Genet 105: 609-615.
33. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
34. Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, Lovestone S et al. (1998). Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality. Neuroreport 9: 1379-1383.
35. Courchesne E, Carper R, Akshoomoff N. (2003). Evidence of brain overgrowth in the first year of life in autism. Jama 290: 337-344.
36. Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, Tigue ZD et al. (2001). Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 57: 245-254.
37. Courchesne E, Redcay E, Kennedy DP. (2004). The autistic brain: birth through adulthood. Curr Opin Neurol 17: 489-496.
38. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G et al. (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 8: 195-208.
39. De Ferrari GV, Inestrosa NC. (2000). Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev 33: 1-12.
40. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131-137.
41. Ertekin-Taner N, Ronald J, Asahara H, Younkin L, Hella M, Jain S et al. (2003). Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Hum Mol Genet 12: 3133-3143.
42. Fatemi SH, Halt AR, Realmuto G, Earle J, Kist DA, Thuras P et al. (2002). Purkinje cell size is reduced in cerebellum of patients with autism. Cell Mol Neurobiol 22: 171-175.
43. Folstein SE, Dowd M, Mankoski R, Tadevosyan O. (2003). How might genetic mechanisms operate in autism? Novartis Found Symp 251: 70-80; discussion 80-73, 109-111, 281-197.
44. Folstein SE, Rosen-Sheidley B. (2001). Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2: 943-955.
45. Ftouh S, Akbar MT, Hirsch SR, de Belleroche JS. (2005). Down-regulation of Dickkopf 3, a regulator of the Wnt signalling pathway, in elderly schizophrenic subjects. J Neurochem 94: 520-530.
46. Gharani N, Benayed R, Mancuso V, Brzustowicz LM, Millonig JH. (2004). Association of the homeobox transcription factor, ENGRAILED 2, 3, with autism spectrum disorder. Mol Psychiatry 9: 474-484.
47. Grove EA, Tole S, Limon J, Yip L, Ragsdale CW. (1998). The hem of the embryonic cerebral cortex is defined by the expression of multiple Wnt genes and is compromised in Gli3-deficient mice. Development 125: 2315-2325.
48. Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R, Mankoo BS et al. (2001). Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. Am J Hum Genet 68: 661-673.
49. Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA et al. (2006). Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 47: 329-335.
50. Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR et al. (2002). Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci 20: 257-270.
51. Hall AC, Lucas FR, Salinas PC. (2000). Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 100: 525-535.
52. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147: 58-62.
53. Hardy J, Selkoe DJ. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
54. Herz J. (2001). The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 29: 571-581.
55. Hey PJ, Twells RC, Phillips MS, Yusuke N, Brown SD, Kawaguchi Y et al. (1998). Cloning of a novel member of the low-density lipoprotein receptor family. Gene 216: 103-111.
56. Houart C, Caneparo L, Heisenberg C, Barth K, Take-Uchi M, Wilson S. (2002). Establishment of the telencephalon during gastrulation by local antagonism of Wnt signaling. Neuron 35: 255-265.
57. Hu-Lince D, Craig DW, Huentelman MJ, Stephan DA. (2005). The Autism Genome Project: goals and strategies. Am J Pharmacogenomics 5: 233-246.
58. Ide M, Muratake T, Yamada K, Iwayama-Shigeno Y, Iwamoto K, Takao H et al. (2004). Genetic and expression analyses of FZD3 in schizophrenia. Biol Psychiatry 56: 462-465.
59. Ingram JL, Peckham SM, Tisdale B, Rodier PM. (2000). Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 22: 319-324.
60. International Molecular Genetic Study of Autism Consortium (IMGSAC). (1998). A full genome screen for autism with evidence for linkage to a region on chromosome 7q. International Molecular Genetic Study of Autism Consortium. Hum Mol Genet 7: 571-578.
61. International Molecular Genetic Study of Autism Consortium (IMGSAC). (2001). A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. Am J Hum Genet 69: 570-581.
62. Jeong SH, Joo EJ, Ahn YM, Lee KY, Kim YS. (2006). Investigation of genetic association between human Frizzled homolog 3 gene (FZD3) and schizophrenia: Results in a Korean population and evidence from meta-analysis. Psychiatry Res 143: 1-11.
63. Joyner AL, Herrup K, Auerbach BA, Davis CA, Rossant J. (1991). Subtle cerebellar phenotype in mice homozygous for a targeted deletion of the En-2 homeobox. Science 251: 1239-1243.
64. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ et al. (2000). Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106: 1159-1166.
65. Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, Zheng H et al. (2002). Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell 110: 751-762.
66. Katsu T, Ujike H, Nakano T, Tanaka Y, Nomura A, Nakata K et al. (2003). The human frizzled-3 (FZD3) gene on chromosome 8p21, a receptor gene for Wnt ligands, is associated with the susceptibility to schizophrenia. Neurosci Lett 353: 53-56.
67. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I et al. (1999). A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 8: 237-245.
68. Kendler KS, Myers JM, O'Neill FA, Martin R, Murphy B, MacLean CJ et al. (2000). Clinical features of schizophrenia and linkage to chromosomes 5q, 6p, 8p, and 10p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 157: 402-408.
69. Kim DH, Inagaki Y, Suzuki T, Ioka RX, Yoshioka SZ, Magoori K et al. (1998). A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. J Biochem (Tokyo) 124: 1072-1076.
70. Klein PS, Melton DA. (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459.
71. Kozlovsky N, Belmaker RH, Agam G. (2000). Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 157: 831-833.
72. Kozlovsky N, Belmaker RH, Agam G. (2001). Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 52: 101-105.
73. Kruglyak L, Nickerson DA. (2001). Variation is the spice of life. Nat Genet 27: 234-236.
74. Lako M, Lindsay S, Bullen P, Wilson DI, Robson SC, Strachan T. (1998). A novel mammalian wnt gene, WNT8B, shows brain-restricted expression in early development, with sharply delimited expression boundaries in the developing forebrain. Hum Mol Genet 7: 813-822.
75. Lau KF, Miller CC, Anderton BH, Shaw PC. (1999). Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 54: 85-91.
76. Lee SM, Tole S, Grove E, McMahon AP. (2000). A local Wnt-3a signal is required for development of the mammalian hippocampus. Development 127: 457-467.
77. Leroy K, Brion JP. (1999). Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanat 16: 279-293.
78. Li J, Nguyen L, Gleason C, Lotspeich L, Spiker D, Risch N et al. (2004). Lack of evidence for an association between WNT2 and RELN polymorphisms and autism. Am J Med Genet B Neuropsychiatr Genet 126: 51-57.
79. Li X, Lu F, Tian Q, Yang Y, Wang Q, Wang JZ. (2006). Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture. J Neural Transm 113: 93-102.
80. Li Y, Cam J, Bu G. (2001). Low-density lipoprotein receptor family: endocytosis and signal transduction. Mol Neurobiol 23: 53-67.
81. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM et al. (1994). Alzheimer's disease-like phosphorylation of the microtubule- associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4: 1077-1086.
82. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. (2001). Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. Embo J 20: 27-39.
83. Magoori K, Kang MJ, Ito MR, Kakuuchi H, Ioka RX, Kamataki A et al. (2003). Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem 278: 11331-11336.
84. Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS. (2005). Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol 167: 107-116.
85. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS. (2003). The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 278: 5947-5951.
86. Mak BC, Yeung RS. (2004). The tuberous sclerosis complex genes in tumor development. Cancer Invest 22: 588-603.
87. Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW et al. (2005). Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci USA 102: 11900-11905.
88. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB et al. (2003). Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci USA 100: 3299-3304.
89. Mateo I, Infante J, Llorca J, Rodriguez E, Berciano J, Combarros O. (2006). Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 21: 228-232.
90. Mayeux R, Lee JH, Romas SN, Mayo D, Santana V, Williamson J et al. (2002). Chromosome-12 mapping of late-onset Alzheimer disease among Caribbean Hispanics. Am J Hum Genet 70: 237-243.
91. McCoy PA, Shao Y, Wolpert CM, Donnelly SL, Ashley-Koch A, Abel HL et al. (2002). No association between the WNT2 gene and autistic disorder. Am J Med Genet 114: 106-109.
92. McGrew LL, Takemaru K, Bates R, Moon RT. (1999). Direct regulation of the Xenopus engrailed-2 promoter by the Wnt signaling pathway, and a molecular screen for Wnt-responsive genes, confirm a role for Wnt signaling during neural patterning in Xenopus. Mech Dev 87: 21-32.
93. McMahon AP, Bradley A. (1990). The Wnt-1 (int-1) protooncogene is required for development of a large region of the mouse brain. Cell 62: 1073-1085.
94. McMahon AP, Joyner AL, Bradley A, McMahon JA. (1992). The midbrain-hindbrain phenotype of Wnt-1-/Wnt-1- mice results from stepwise deletion of engrailed-expressing cells by 9.5 days postcoitum. Cell 69: 581-595.
95. Millen KJ, Wurst W, Herrup K, Joyner AL. (1994). Abnormal embryonic cerebellar development and patterning of postnatal foliation in two mouse Engrailed-2 mutants. Development 120: 695-706.
96. Miyaoka T, Seno H, Ishino H. (1999). Increased expression of Wnt-1 in schizophrenic brains. Schizophr Res 38: 1-6.
97. Miyazaki K, Narita N, Narita M. (2005). Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int J Dev Neurosci 23: 287-297.
98. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. (2004). WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
99. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T et al. (2000). A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37: 489-497.
100. Mudher A, Chapman S, Richardson J, Asuni A, Gibb G, Pollard C et al. (2001). Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J Neurosci 21: 4987-4995.
101. Mudher A, Lovestone S. (2002). Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26.
102. Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D et al. (2002). Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet 114: 235-244.
103. Packard M, Koo ES, Gorczyca M, Sharpe J, Cumberledge S, Budnik V. (2002). The Drosophila Wnt, Wingless, provides an essential signal for pre- and postsynaptic differentiation. Cell 111: 319-330.
104. Panakova D, Sprong H, Marois E, Thiele C, Eaton S. (2005). Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 435: 58-65.
105. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B et al. (1999). Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58: 1010-1019.
106. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA et al. (1997). Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. Jama 278: 1237-1241.
107. Petit E, Herault J, Martineau J, Perrot A, Barthelemy C, Hameury L et al. (1995). Association study with two markers of a human homeogene in infantile autism. J Med Genet 32: 269-274.
108. Phiel CJ, Wilson CA, Lee VM, Klein PS. (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439.
109. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
110. Philippe A, Martinez M, Guilloud-Bataille M, Gillberg C, Rastam M, Sponheim E et al. (1999). Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum Mol Genet 8: 805-812.
111. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. (2000). An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407: 535-538.
112. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blouin JL et al. (1995). Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. Am J Med Genet 60: 252-260.
113. Rapoport JL, Addington AM, Frangou S, Psych MR. (2005). The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10: 434-449.
114. Rebeck GW, Kindy M, LaDu MJ. (2002). Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis 4: 145-154.
115. Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, Hallmayer J et al. (1999). A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet 65: 493-507.
116. Ritvo ER, Freeman BJ, Scheibel AB, Duong T, Robinson H, Guthrie D et al. (1986). Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am J Psychiatry 143: 862-866.
117. Rodier PM, Ingram JL, Tisdale B, Croog VJ. (1997). Linking etiologies in humans and animal models: studies of autism. Reprod Toxicol 11: 417-422.
118. Rogaeva E, Premkumar S, Song Y, Sorbi S, Brindle N, Paterson A et al. (1998). Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. Jama 280: 614-618.
119. Russ C, Lovestone S, Powell JF. (2001). Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol Psychiatry 6: 320-324.
120. Russ C, Lovestone S, Powell JF. (2002). Identification of genomic organisation, sequence variants and analysis of the role of the human dishevelled 1 gene in late onset Alzheimer's disease. Mol Psychiatry 7: 104-109.
121. Sala CF, Formenti E, Terstappen GC, Caricasole A. (2000). Identification, gene structure, and expression of human frizzled-3 (FZD3). Biochem Biophys Res Commun 273: 27-34.
122. Salinas PC. (1999). Wnt factors in axonal remodelling and synaptogenesis. Biochem Soc Symp 65: 101-109.
123. Salinas PC. (2005). Signaling at the vertebrate synapse: new roles for embryonic morphogens? J Neurobiol 64: 435-445.
124. Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T et al. (2002). Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomerictau fibrils in COS-7 cells. J Biol Chem 277: 42060-42065.
125. Saunders AJ, Bertram L, Mullin K, Sampson AJ, Latifzai K, Basu S et al. (2003). Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet 12: 2765-2776.
126. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
127. Scassellati C, Bonvicini C, Perez J, Bocchio-Chiavetto L, Tura GB, Rossi G et al. (2004). Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia. Neuropsychobiology 50: 16-20.
128. Schumann CM, Hamstra J, Goodlin-Jones BL, Lotspeich LJ, Kwon H, Buonocore MH et al. (2004). The amygdala is enlarged in children but not adolescents with autism; the hippocampus is enlarged at all ages. J Neurosci 24: 6392-6401.
129. Scott WK, Grubber JM, Conneally PM, Small GW, Hulette CM, Rosenberg CK et al. (2000). Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J Hum Genet 66: 922-932.
130. Shaw PC, Davies AF, Lau KF, Garcia-Barcelo M, Waye MM, Lovestone S et al. (1998). Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes. Genome 41: 720-727.
131. Sparks BF, Friedman SD, Shaw DW, Aylward EH, Echelard D, Artru AA et al. (2002). Brain structural abnormalities in young children with autism spectrum disorder. Neurology 59: 184-192.
132. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS et al. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977-1981.
133. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H et al. (2002). Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321: 61-64.
134. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M et al. (2003). Diverse psychotomimetics act through a common signaling pathway. Science 302: 1412-1415.
135. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M et al. (1998a). Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31: 317-323.
136. Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K et al. (1998b). Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci USA 95: 9637-9641.
137. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y et al. (2000). LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 530-535.
138. Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL. (2005). Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 8: 1727-1734.
139. Teter B, Raber J, Nathan B, Crutcher KA. (2002). The presence of apoE4, not the absence of apoE3, contributes to AD pathology. J Alzheimers Dis 4: 155-163.
140. Thomas KR, Capecchi MR. (1990). Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature 346: 847-850.
141. Thomas KR, Musci TS, Neumann PE, Capecchi MR. (1991). Swaying is a mutant allele of the proto-oncogene Wnt-1. Cell 67: 969-976.
142. van Meurs JB, Rivadeneira F, Jhamai M, Hugens W, Hofman A, van Leeuwen JP et al. (2006). Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J Bone Miner Res 21: 141-150.
143. Vogel MW, Ji Z, Millen K, Joyner AL. (1996). The Engrailed-2 homeobox gene and patterning of spinocerebellar mossy fiber afferents. Brain Res Dev Brain Res 96: 210-218.
144. Vorstman JA, Staal WG, van Daalen E, van Engeland H, Hochstenbach PF, Franke L. (2006). Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism. Mol Psychiatry 11: 1, 18-28..
145. Wang J, Jing Z, Zhang L, Zhou G, Braun J, Yao Y et al. (2003). Regulation of acetylcholine receptor clustering by the tumor suppressor APC. Nat Neurosci 6: 1017-1018.
146. Wang Y, Thekdi N, Smallwood PM, Macke JP, Nathans J. (2002). Frizzled-3 is required for the development of major fiber tracts in the rostral CNS. J Neurosci 22: 8563-8573.
147. Warwick Daw E, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD et al. (2000). The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 66: 196-204.
148. Wassink TH, Piven J, Vieland VJ, Huang J, Swiderski RE, Pietila J et al. (2001). Evidence supporting WNT2 as an autism susceptibility gene. Am J Med Genet 105: 406-413.
149. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D et al. (2000). arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 407: 527-530.
150. Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH. (2001). Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 43: 202-206.
151. Williams PG, Hersh JH. (1997). A male with fetal valproate syndrome and autism. Dev Med Child Neurol 39: 632-634.
152. Wilson SW, Houart C. (2004). Early steps in the development of the forebrain. Dev Cell 6: 167-181.
153. Wiznitzer M. (2004). Autism and tuberous sclerosis. J Child Neurol 19: 675-679.
154. Wu WS, Holmans P, Wavrant-DeVrieze F, Shears S, Kehoe P, Crook R et al. (1998). Genetic studies on chromosome 12 in late-onset Alzheimer disease. Jama 280: 619-622.
155. Yang J, Si T, Ling Y, Ruan Y, Han Y, Wang X et al. (2003). Association study of the human FZD3 locus with schizophrenia. Biol Psychiatry 54: 1298-1301.
156. Ylisaukko-oja T, Nieminen-von Wendt T, Kempas E, Sarenius S, Varilo T, von Wendt L et al. (2004). Genome-wide scan for loci of Asperger syndrome. Mol Psychiatry 9: 161-168.
157. Zhang Y, Yu X, Yuan Y, Ling Y, Ruan Y, Si T et al. (2004). Positive association of the human frizzled 3 (FZD3) gene haplotype with schizophrenia in Chinese Han population. Am J Med Genet B Neuropsychiatr Genet 129: 16-19.
158. Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M et al. (1998). Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395: 698-702.
159. Zhong H, Serajee FJ, Nabi R, Huq AH. (2003). No association between the EN2 gene and autistic disorder. J Med Genet 40: e4.
160. Zhou CJ, Pinson KI, Pleasure SJ. (2004). Severe defects in dorsal thalamic development in low-density lipoprotein receptor-related protein-6 mutants. J Neurosci 24: 7632-7639.
161. Zhou J, Liyanage U, Medina M, Ho C, Simmons AD, Lovett M et al. (1997). Presenilin 1 interaction in the brain with a novel member of the Armadillo family. Neuroreport 8: 2085-2090.